The DOI matches its Crossref record; 475 of the 475 references it cites were found in a registry or an index.
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Open accessAbstract
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs. They created combinatorial antibody libraries on filamentous phage to be utilized for generating antigen specific antibodies in a matter of weeks. Since then, more than 70 phage–derived antibodies entered clinical studies and 14 of them have been approved. These antibodies are indicated for cancer, and non-cancer medical conditions, such as inflammatory, optical, infectious, or immunological diseases. Antibody phage display has proven to be a powerful, versatile platform for antibodies discovery and development. This review will illustrate the utility of phage display as a powerful platform for therapeutic antibodies discovery and describe in detail all the approved mAbs derived from phage display.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“Atezolizumab as a single treatment has shown a significant anti-tumor response in NSCLC (469, 474–476), UC (466, 477), glioblastoma multiforme (478), and RCC (479).”
BackgroundNaturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
MEMBRANE PROTEIN FOLDING AND STABILITY: Physical Principles
White, S. H., & Wimley, W. C. (1999) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.28.1.319 · Cited by 1,764
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,748
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Innate IL-17-producing cells: the sentinels of the immune system
Cua, D. J., & Tato, C. M. (2010) · Nature Reviews Immunology · doi:10.1038/nri2800 · Cited by 1,578
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Smith, G. P., & Petrenko, V. A. (1997) · Chemical Reviews · doi:10.1021/cr960065d · Cited by 1,548
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Canonical structures for the hypervariable regions of immunoglobulins
Chothia, C., & Lesk, A. M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90412-8 · Cited by 1,406
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · cited 1×
“While ADCC has not been indicated to contribute to the clinical activity of avelumab (472), preclinical studies suggest a possible role of ADCC in the activity of avelumab (481, 482).”
BackgroundThe Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
Making antibody fragments using phage display libraries
Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991) · Nature · doi:10.1038/352624a0 · Cited by 1,203
Conformations of immunoglobulin hypervariable regions
Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., et al. (1989) · Nature · doi:10.1038/342877a0 · Cited by 1,185
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.
Barbas, C. F., Kang, A. S., Lerner, R. A., & Benkovic, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.7978 · Cited by 1,183
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., et al. (2002) · JAMA · doi:10.1001/jama.287.17.2236 · Cited by 1,027
Biopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · cited 2×
“They represent six of the top ten selling drugs (7) with annual sales exceeding $120 billion in 2017 (8) and are expected to reach $130–200 billion by 2022 (9).”
BackgroundIsolation of high affinity human antibodies directly from large synthetic repertoires.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., & Allison, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06626.x · Cited by 962
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
Henter, J.-I. (2002) · Blood · doi:10.1182/blood-2002-01-0172 · Cited by 900
Antibody-selectable filamentous fd phage vectors: affinity purification of target genes
Parmley, S. F., & Smith, G. P. (1988) · Gene · doi:10.1016/0378-1119(88)90495-7 · Cited by 867
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities
Xu, J. L., & Davis, M. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00006-6 · Cited by 779
[15] Libraries of peptides and proteins displayed on filamentous phage
Smith, G. P., & Scott, J. K. (1993) · Methods in Enzymology · doi:10.1016/0076-6879(93)17065-d · Cited by 769
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Standard conformations for the canonical structures of immunoglobulins 1 1Edited by I. A. Wilson
Al-Lazikani, B., Lesk, A. M., & Chothia, C. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1354 · Cited by 706
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629 · cited 2×
“Other antibody quality attributes, such as solubility, viscosity, expression yield, and thermal and long-term stability are vital to ensure the success of mAb lead candidates in biomanufacturing and clinical trials (95, 96).”
BackgroundGurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 9×
“P h a g e D isp la y D e rive d M o n o c lo n a lA n tib o d ie s TABLE 2 | Continued Product name/Brand name Antibody format Target antigen Antibody phage display type Phage display technology Clinical domain Indication(s) Highest development phase Sponsor company Raxibacumab/ABthrax® IgG1-λ Anthrax PA, Bacillus ant…”
BackgroundInfluentialDesign of therapeutic proteins with enhanced stability
Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904191106 · Cited by 598
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Colman, R. W., & Schmaier, A. H. (1997) · Blood · doi:10.1182/blood.v90.10.3819 · Cited by 581
Synthesis and release of B-lymphocyte stimulator from myeloid cells
Nardelli, B., Belvedere, O., Roschke, V., Moore, P. A., Olsen, H. S., Migone, T. S., Sosnovtseva, S., Carrell, J. A., Feng, P., Giri, J. G., et al. (2001) · Blood · doi:10.1182/blood.v97.1.198 · Cited by 576
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · cited 2×
“library (170) Neurology (423) Alzheimer’s”
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Familial Haemophagocytic Reticulosis
Farquhar, J. W., & Claireaux, A. E. (1952) · Archives of Disease in Childhood · doi:10.1136/adc.27.136.519 · Cited by 552
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 541
de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruı̈ne, A. P., Arends, J.-W., & Hoogenboom, H. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18218 · Cited by 533
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy264 · Cited by 501
Phage display: Concept, innovations, applications and future
Pande, J., Szewczyk, M. M., & Grover, A. K. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.07.004 · Cited by 492
Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., Ramlau, R., Galiulin, R. K., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 479
Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 462
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Thrombotic thrombocytopenic purpura
Hovinga, J. A. K., Coppo, P., Lämmle, B., Moake, J. L., Miyata, T., & Vanhoorelbeke, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.20 · Cited by 427
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 422
Filamentous Phage Display in the New Millennium
Kehoe, J. W., & Kay, B. K. (2005) · Chemical Reviews · doi:10.1021/cr000261r · Cited by 413
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Kang, A. S., Barbas, C. F., Janda, K. D., Benkovic, S. J., & Lerner, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4363 · Cited by 411
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
DeKosky, B. J., Ippolito, G. C., Deschner, R. P., Lavinder, J. J., Wine, Y., Rawlings, B. M., Varadarajan, N., Giesecke, C., Dörner, T., Andrews, S. F., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2492 · Cited by 410
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Nucleotide sequence of the filamentous bacteriophage M13 DNA genome: comparison with phage fd
van Wezenbeek, P. M. G. F., Hulsebos, T. J. M., & Schoenmakers, J. G. G. (1980) · Gene · doi:10.1016/0378-1119(80)90093-1 · Cited by 408
Dewald, G., & Bork, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.092 · Cited by 402
Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., Özgüroğlu, M., Szczesna, A., Polychronis, A., Uslu, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30673-9 · Cited by 399
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Mendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X.-C., Maynard-Currie, C. E., Yang, X.-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376
Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem.
Barbas, C. F., Bain, J. D., Hoekstra, D. M., & Lerner, R. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4457 · Cited by 375
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
Fellouse, F. A., Esaki, K., Birtalan, S., Raptis, D., Cancasci, V. J., Koide, A., Jhurani, P., Vasser, M., Wiesmann, C., Kossiakoff, A. A., et al. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.08.005 · Cited by 358
Five computational developability guidelines for therapeutic antibody profiling
Raybould, M. I. J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810576116 · Cited by 357
Hormone phage: An enrichment method for variant proteins with altered binding properties
Bass, S., Greene, R., & Wells, J. A. (1990) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340080405 · Cited by 356
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Interleukin‐23: as a drug target for autoimmune inflammatory diseases
Tang, C., Chen, S., Qian, H., & Huang, W. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03522.x · Cited by 337
Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
Söderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Åberg, A.-M., Nilsson, A., Jansson, B., Ohlin, M., Wingren, C., et al. (2000) · Nature Biotechnology · doi:10.1038/78458 · Cited by 337
Hornig, B., Kohler, C., & Drexler, H. (1997) · Circulation · doi:10.1161/01.cir.95.5.1115 · Cited by 333
G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
Scapini, P., Nardelli, B., Nadali, G., Calzetti, F., Pizzolo, G., Montecucco, C., & Cassatella, M. A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021343 · Cited by 324
Filamentous Bacteriophage: Biology, Phage Display and Nanotechnology Applications
(2011) · Current Issues in Molecular Biology · doi:10.21775/cimb.013.051 · Cited by 321
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Banerji, A., Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., et al. (2018) · JAMA · doi:10.1001/jama.2018.16773 · Cited by 312
Selecting high-affinity binding proteins by monovalent phage display
Lowman, H. B., Bass, S. H., Simpson, N., & Wells, J. A. (1991) · Biochemistry · doi:10.1021/bi00109a004 · Cited by 311
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 2×
“(HGS-ETR2) IgG1-λ TRAIL-R2 (DR5) Naïve scFv (79, 253) CAT Oncology”
BackgroundLach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
A surface expression vector for antibody screening
Breitling, F., Dübel, S., Seehaus, T., Klewinghaus, I., & Little, M. (1991) · Gene · doi:10.1016/0378-1119(91)90244-6 · Cited by 305
Heery, C. R., O'Sullivan-Coyne, G., Madan, R. A., Cordes, L., Rajan, A., Rauckhorst, M., Lamping, E., Oyelakin, I., Marté, J. L., Lepone, L. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30239-5 · Cited by 305
A helper phage to improve single-chain antibody presentation in phage display
Rondot, S., Koch, J., Breitling, F., & Dübel, S. (2001) · Nature Biotechnology · doi:10.1038/83567 · Cited by 300
Antibodies from phage antibody libraries
Bradbury, A. R. M., & Marks, J. D. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.007 · Cited by 296
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 296
Raxibacumab for the Treatment of Inhalational Anthrax
Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810603 · Cited by 294
Targeting CD73 in the tumor microenvironment with MEDI9447
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 287
Gulley, J. L., Rajan, A., Spigel, D. R., Iannotti, N., Chandler, J., Wong, D. J. L., Leach, J., Edenfield, W. J., Wang, D., Grote, H. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30240-1 · Cited by 286
COVID-19 and Cancer: a Comprehensive Review
Gosain, R., Abdou, Y., Singh, A., Rana, N., Puzanov, I., & Ernstoff, M. S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00934-7 · Cited by 285
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Human T H 17 Cells Are Long-Lived Effector Memory Cells
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278
The ErbB Receptors and their Ligands in Cancer: An Overview
Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M., Luca, A., Caponigro, F., & Salomon, D. (2005) · Current Drug Targets · doi:10.2174/1389450053765879 · Cited by 275
Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, L., Frederiksen, J., Skeen, M., Jaffe, G. J., Butzkueven, H., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30377-5 · Cited by 273
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
Proteolytic selection for protein folding using filamentous bacteriophages
Kristensen, P. K., & Winter, G. P. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00044-3 · Cited by 272
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 264
Normal B Cell Homeostasis Requires B Cell Activation Factor Production by Radiation-resistant Cells
Gorelik, L., Gilbride, K., Dobles, M., Kalled, S. L., Zandman, D., & Scott, M. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030789 · Cited by 258
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Kreitman, R. J., Dearden, C., Zinzani, P. L., Delgado, J., Karlin, L., Robak, T., Gladstone, D. E., le Coutre, P., Dietrich, S., Gotic, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0210-1 · Cited by 251
Golfier, S., Kopitz, C., Kahnert, A., Heisler, I., Schatz, C. A., Stelte-Ludwig, B., Mayer-Bartschmid, A., Unterschemmann, K., Bruder, S., Linden, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0926 · Cited by 249
Rothe, C., Urlinger, S., Löhning, C., Prassler, J., Stark, Y., Jäger, U., Hubner, B., Bardroff, M., Pradel, I., Boss, M., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.12.018 · Cited by 247
Yen, W.-C., Fischer, M. M., Axelrod, F., Bond, C., Cain, J., Cancilla, B., Henner, W. R., Meisner, R., Sato, A., Shah, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2808 · Cited by 246
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Caplacizumab: First Global Approval
Duggan, S. (2018) · Drugs · doi:10.1007/s40265-018-0989-0 · Cited by 245
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27189 · Cited by 243
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Inman, B. A., Longo, T. A., Ramalingam, S., & Harrison, M. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1417 · Cited by 238
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Smith, N. R., Baker, D., James, N. H., Ratcliffe, K., Jenkins, M., Ashton, S. E., Sproat, G., Swann, R., Gray, N., Ryan, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2797 · Cited by 237
Application of phage display to high throughput antibody generation and characterization
Schofield, D. J., Pope, A. R., Clementel, V., Buckell, J., Chapple, S. D., Clarke, K. F., Conquer, J. S., Crofts, A. M., Crowther, S. R., Dyson, M. R., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-11-r254 · Cited by 236
Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 236
Basics of Antibody Phage Display Technology
Ledsgaard, L., Kilstrup, M., Karatt-Vellatt, A., McCafferty, J., & Laustsen, A. H. (2018) · Toxins · doi:10.3390/toxins10060236 · Cited by 236
Panettieri, R. A., Sjöbring, U., Péterffy, A., Wessman, P., Bowen, K., Piper, E., Colice, G., & Brightling, C. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30184-x · Cited by 235
Selective targeted delivery of TNFα to tumor blood vessels
Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Birò, A., Siri, A., Orecchia, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1039 · Cited by 234
Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G., & Hoogenboom, H. R. (1994) · Nature Biotechnology · doi:10.1038/nbt0994-899 · Cited by 233
Self-citationAntibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Kreitman, R. J., & Pastan, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0487 · Cited by 231
Villa, A., Trachsel, E., Kaspar, M., Schliemann, C., Sommavilla, R., Rybak, J., Rösli, C., Borsi, L., & Neri, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23408 · Cited by 228
Novak, A. J., Bram, R. J., Kay, N. E., & Jelinek, D. F. (2002) · Blood · doi:10.1182/blood-2002-02-0558 · Cited by 224
Chowdhury, P. S., Viner, J. L., Beers, R., & Pastan, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.669 · Cited by 222
Engineering M13 for phage display
Sidhu, S. S. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00087-9 · Cited by 221
Phage display of combinatorial antibody libraries
Rader, C., & Barbas, C. F. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80075-4 · Cited by 220
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Chavez, J. C., Bachmeier, C., & Kharfan-Dabaja, M. A. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719841581 · Cited by 220
Anthrax lethal and edema toxins in anthrax pathogenesis
Liu, S., Moayeri, M., & Leppla, S. H. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.02.012 · Cited by 217
Brana, I., Calles, A., LoRusso, P. M., Yee, L. K., Puchalski, T. A., Seetharam, S., Zhong, B., de Boer, C. J., Tabernero, J., & Calvo, E. (2015) · Targeted Oncology · doi:10.1007/s11523-014-0320-2 · Cited by 216
Kimball, A. B. (2008) · Archives of Dermatology · doi:10.1001/archdermatol.2007.63 · Cited by 214
Antibody Phage Display: Technique and Applications
Hammers, C. M., & Stanley, J. R. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.521 · Cited by 212
Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries
Krag, D. N., Shukla, G. S., Shen, G.-P., Pero, S., Ashikaga, T., Fuller, S., Weaver, D. L., Burdette-Radoux, S., & Thomas, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4441 · Cited by 212
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
Liu, L., Kikly, K., Lu, J., Allan, B., Tang, Y., Tetreault, J., Chow, C.-K., Barmettler, B., Nelson, J., Bina, H., et al. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s100940 · Cited by 208
Contact pathway of coagulation and inflammation
Wu, Y. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0048-y · Cited by 206
Tiller, T., Schuster, I., Deppe, D., Siegers, K., Strohner, R., Herrmann, T., Berenguer, M., Poujol, D., Stehle, J., Stark, Y., et al. (2013) · mAbs · doi:10.4161/mabs.24218 · Cited by 205
Prediction of aggregation prone regions of therapeutic proteins
Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp911706q · Cited by 200
Lavie, F., Miceli‐Richard, C., Quillard, J., Roux, S., Leclerc, P., & Mariette, X. (2004) · The Journal of Pathology · doi:10.1002/path.1533 · Cited by 193
Sarkar, C. A., Dodevski, I., Kenig, M., Dudli, S., Mohr, A., Hermans, E., & Plückthun, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803103105 · Cited by 192
Dörner, T., Posch, M. G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J. M., Kamphausen, E., Valentin, M.-A., Simonett, C., Mooney, L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214720 · Cited by 192
Zhu, Z., Bossart, K. N., Bishop, K. A., Crameri, G., Dimitrov, A. S., McEachern, J. A., Feng, Y., Middleton, D., Wang, L.-F., Broder, C. C., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/528801 · Cited by 187
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan, R., Ebel, W., Routhier, E., Patel, R. K., Kline, J. B., Zhang, J., Chao, Q., Jacob, S. M., Turchin, H. A., Gibbs, L. S., et al. (2007) · PubMed · Cited by 186
Cadavid, D., Mellion, M., Hupperts, R., Edwards, K. R., Calabresi, P. A., Drulović, J., Giovannoni, G., Hartung, H.-P., Arnold, D. L., Fisher, E., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30137-1 · Cited by 185
Ulrichts, H., Silence, K., Schoolmeester, A., de Jaegere, P., Rossenu, S., Roodt, J., Priem, S., Lauwereys, M., Casteels, P., Van Bockstaele, F., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317859 · Cited by 184
Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
Johannsen, M., Spitaleri, G., Curigliano, G., Roigas, J., Weikert, S., Kempkensteffen, C., Roemer, A., Kloeters, C., Rogalla, P., Pecher, G., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.033 · Cited by 183
Novel TGF-β inhibitors ready for prime time in onco-immunology
de Gramont, A., Faivre, S., & Raymond, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1257453 · Cited by 183
Simpson, A., Petnga, W., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 183
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 183
Deodhar, A., Gottlieb, A. B., Boehncke, W.-H., Dong, B., Wang, Y., Zhuang, Y., Barchuk, W., Xu, X. L., Hsia, E. C., AELION, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30952-8 · Cited by 183
GAUDREAULT, J., FEI, D., BEYER, J. C., RYAN, A., RANGELL, L., SHIU, V., & DAMICO, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318134eecd · Cited by 181
Antibody Engineering for Pursuing a Healthier Future
Saeed, A. F. U. H., Wang, R., Ling, S., & Wang, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00495 · Cited by 181
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500815200 · Cited by 180
Hassan, R., Kindler, H. L., Jahan, T., Bazhenova, L., Reck, M., Thomas, A., Pastan, I., Parno, J., O'Shannessy, D. J., Fatato, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0804 · Cited by 180
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells
Ho, M., Nagata, S., & Pastan, I. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603653103 · Cited by 179
Selectivity of BAFF/BLyS and APRIL for Binding to the TNF Family Receptors BAFFR/BR3 and BCMA
Day, E. S., Cachero, T. G., Qian, F., Sun, Y., Wen, D., Pelletier, M., Hsu, Y.-M., & Whitty, A. (2005) · Biochemistry · doi:10.1021/bi048227k · Cited by 176
Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C
Brack, S. S., Silacci, M., Birchler, M., & Neri, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2804 · Cited by 176
Isolation of human monoclonal antibodies by mammalian cell display
Beerli, R. R., Bauer, M., Buser, R. B., Gwerder, M., Muntwiler, S., Maurer, P., Saudan, P., & Bachmann, M. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805942105 · Cited by 176
Antibody Aggregation: Insights from Sequence and Structure
Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D. S. (2016) · Antibodies · doi:10.3390/antib5030019 · Cited by 174
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 174
Le Tourneau, C., Hoimes, C., Zarwan, C., Wong, D. J., Bauer, S., Claus, R., Wermke, M., Hariharan, S., von Heydebreck, A., Kasturi, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0424-9 · Cited by 173
Aggregation, stability, and formulation of human antibody therapeutics
Lowe, D., Dudgeon, K., Rouet, R., Schofield, P., Jermutus, L., & Christ, D. (2011) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/b978-0-12-386483-3.00004-5 · Cited by 172
Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., Castellano, D., Hussain, S., Fléchon, A., Bamias, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32365-6 · Cited by 171
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
Vallurupalli, M., & Berliner, N. (2019) · Blood · doi:10.1182/blood.2019002289 · Cited by 170
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
Pung, H. S., Tye, G. J., Leow, C. H., Ng, W. K., & Lai, N. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08380-x · Cited by 30
Generation and diversification of recombinant monoclonal antibodies
DeLuca, K. F., Mick, J. E., Ide, A. H., Lima, W. C., Sherman, L., Schaller, K. L., Anderson, S. M., Zhao, N., Stasevich, T. J., Varma, D., et al. (2021) · eLife · doi:10.7554/elife.72093 · Cited by 21
Arsiwala, A., Bhatt, R., van Niekerk, L., Quintero-Cadena, P., Ao, X., Rosenbaum, A., Bhatt, A., Smith, A., Yang, Y., Anderson, K., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2593055 · Cited by 16
Metadata
- Authors
- Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-28
- Volume
- 11
- Pages
- 1986-1986
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3044690826
- Cited by
- 273
- References
- 475
- FWCI
- 14.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.